At the end of June this year, Millennium Pharmaceuticals entered into an agreement with Johnson & Johnson’s subsidiary Ortho Biotech Products for Millennium’s anticancer drug Velcade® (bortezomib) which reduced Millennium’s share down 13% to US$13.69. This article examines Millennium’s development strategy regarding this deal and attempts to assess reasons for the market’s negative reaction.